Clinical Study Results
Adverse events may or may not be caused by the treatments in the study. A lot of
research is needed to know whether a treatment causes an adverse event.
The table below includes a summary of the adverse events the participants had in
Part B:
Part B
Adavosertib and olaparib
(Out of 9 participants)
100%
How many participants in Part B had adverse events?
(9)
33.3%
How many participants in Part B had serious adverse events?
(3)
How many participants in Part B stopped taking 1 of the 0.0%
study treatments because of adverse events? (0)
11.1%
How many participants died due to serious adverse events?
(1)
The most common adverse events were low numbers of blood-clotting fragments
called platelets, and low numbers of red blood cells. This is also called anemia.
There were 3 participants who had serious adverse events during Part B of the
study. These were fever in a participant with low numbers of white blood cells, a
urinary tract infection, and pneumonia.
What medical problems did participants have
during the study?
This section is a summary of the medical problems the participants had during
the study that the study doctors thought might be related to the study treatments.
These medical problems are called “adverse reactions”. An adverse reaction
is considered “serious” when it is life-threatening, causes lasting problems, or
requires hospital care.
10